The Technical Analyst
Avid Bioservices Inc [CDMO]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Avid Bioservices Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-3.99% $6.26
America/New_York / 19 apr 2024 @ 13:05
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 395.88 mill |
| EPS: | -0.180 |
| P/E: | -34.78 |
| Earnings Date: | Apr 18, 2024 |
| SharesOutstanding: | 63.24 mill |
| Avg Daily Volume: | 1.345 mill |
| RATING 2024-04-19 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -34.78 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -5.92x |
| Company: PE -34.78 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 5.76 - 6.77 ( +/- 8.07%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-11 | Kwietniak Matthew R. | Sell | 669 | Restricted Stock Units |
| 2024-04-11 | Kwietniak Matthew R. | Buy | 669 | Common Stock, $0.001 par value |
| 2024-04-09 | Ziebell Mark R | Buy | 1 251 | Common Stock, $0.001 par value |
| 2024-04-09 | Ziebell Mark R | Buy | 1 261 | Common Stock, $0.001 par value |
| 2024-04-09 | Ziebell Mark R | Buy | 696 | Common Stock, $0.001 par value |
| INSIDER POWER |
|---|
| 41.08 |
| Last 100 transactions |
| Buy: 323 693 | Sell: 129 909 |
Forecast:
14:44 - $6.27
Live Trading Signals (every 1 min)
Forecast
1: 13:14 - $6.26
Forecast 2: 14:04 - $6.26
Forecast 3: 14:44 - $6.27
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $6.26 (-3.99% ) |
| Volume | 0.361 mill |
| Avg. Vol. | 1.345 mill |
| % of Avg. Vol | 26.81 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CDMO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $6.59 | N/A | Active |
|---|
CDMO
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
Latest Press Releases
2024-04-12 14:25:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Avid Bioservices, Inc. - Cdmo
New york , april 12, 2024 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of avid bioservices, inc. ("avid" or the "company") (nasdaq: cdmo). such investors are advised to contact danielle peyton at newaction@pomlaw.com or 646-581-9980, ext.
2024-04-04 19:10:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Avid Bioservices, Inc. - Cdmo
New york , april 4, 2024 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of avid bioservices, inc. ("avid" or the "company") (nasdaq: cdmo). such investors are advised to contact danielle peyton at newaction@pomlaw.com or 646-581-9980, ext.
2024-03-27 17:05:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Avid Bioservices, Inc. - Cdmo
New york , march 27, 2024 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of avid bioservices, inc. ("avid" or the "company") (nasdaq: cdmo). such investors are advised to contact danielle peyton at newaction@pomlaw.com or 646-581-9980, ext.
2024-03-20 07:00:00 - Press Release
Avid Bioservices Announces Receipt Of Deficiency Notice From Nasdaq Regarding Late Form 10-q
Tustin, calif., march 20, 2024 (globe newswire) -- avid bioservices, inc. (nasdaq:cdmo), a dedicated biologics contract development and manufacturing organization (cdmo), announced today it received a notice (the “notice”) on march 19, 2024 from the listing qualifications department of the nasdaq stock market llc (“nasdaq”) advising the company that it was not in compliance with nasdaq's continued listing requirements under nasdaq listing rule 5250(c)(1) (the “rule”) as a result of its failure to file its quarterly report on form 10-q for the fiscal quarter ended january 31, 2024 (the “form 10-q”) in a timely manner.
2024-03-14 14:12:00 - Press Release
Glancy Prongay & Murray Llp, A Leading Securities Fraud Law Firm, Announces Investigation Of Avid Bioservices, Inc. (cdmo) On Behalf Of Investors
Los angeles--(business wire)--glancy prongay & murray llp (“gpm”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of avid bioservices, inc. (“avid” or the “company”) (nasdaq: cdmo) investors concerning the company's possible violations of the federal securities laws. if you suffered a loss on your avid investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws.
Latest News
2024-03-07 09:05:51 - InvestorPlace
Why Is Avid Bioservices (CDMO) Stock Down 30% Today?
Avid Bioservices (NASDAQ: CDMO ) stock is falling on Thursday after the contract development and manufacturing company announced the pricing of a private placement. The private placement includes 7.00% Convertible Senior Notes due 2029 with an aggregate principal amount of $160 million.
2024-01-07 02:58:30 - Seeking Alpha
Avid Bioservices: Don't Miss The Bigger Picture
Avid Bioservices has invested heavily in building new facilities, causing lower margins and negative free cash flow. The company's recent expansion projects have increased its revenue capacity to $400 million, with expected adjusted EBITDA margins in the low to mid 30s. Despite the investments, the company's guidance for the current fiscal year implies limited growth due to a shift in project types and the new facility not being fully operational yet.
2023-12-08 09:35:13 - InvestorPlace
Why Is Avid Bioservices (CDMO) Stock Down 18% Today?
Avid Bioservices (NASDAQ: CDMO ) stock is falling on Friday following the release of its earnings report for its fiscal second quarter of 2024. Avid Bioservices reported adjusted earnings per share of -12 cents alongside revenue of $25.4 million.
2023-12-07 21:54:29 - InvestorPlace
CDMO Stock Earnings: Avid Bioservices Misses EPS, Misses Revenue for Q2 2024
Avid Bioservices (NASDAQ: CDMO ) just reported results for the second quarter of 2024. Avid Bioservices reported earnings per share of -12 cents.
2023-12-07 21:44:08 - Seeking Alpha
Avid Bioservices, Inc. (CDMO) Q2 2024 Earnings Call Transcript
Avid Bioservices, Inc. (NASDAQ:CDMO ) Q2 2024 Earnings Conference Call December 7, 2023 4:30 PM ET Company Participants Tim Brons - Investors Relations Group Nick Green - President and CEO Dan Hart - Chief Financial Officer Matt Kwietniak - Chief Commercial Officer Conference Call Participants Jacob Johnson - Stephens Matt Hewitt - Craig-Hallum Paul Knight - KeyBanc Max Smock - William Blair Thomas Kelliher - RBC Capital Markets Operator Good day, ladies and gentlemen. And welcome to the Avid Bioservices Second Quarter Fiscal 2024 Financial Results Conference Call.
2023-12-07 18:48:19 - Zacks Investment Research
Avid Bioservices (CDMO) Reports Q2 Loss, Lags Revenue Estimates
Avid Bioservices (CDMO) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.01 per share a year ago.
2023-11-30 16:05:00 - GlobeNewsWire
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2024 After Market Close on December 7, 2023
TUSTIN, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the second quarter of fiscal year 2024 on December 7, 2023, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the second quarter and review recent corporate developments.
2023-11-28 11:17:41 - Zacks Investment Research
Down -22.27% in 4 Weeks, Here's Why Avid Bioservices (CDMO) Looks Ripe for a Turnaround
Avid Bioservices (CDMO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
2023-11-27 08:45:53 - MarketBeat
From laggards to leaders: Small caps on the rise
Stocks driving that large-cap index performance include names you've become familiar with this year, such as Nvidia Corp. NASDAQ: NVDA, Tesla Inc. NASDAQ: TSLA and Meta Platforms Inc. NASDAQ: META, but also Royal Caribbean Cruises Ltd. NYSE: RCL and PulteGroup Inc. NYSE: PHM.
2023-11-15 05:16:03 - Zacks Investment Research
Avid Bioservices (CDMO) Moves 9.0% Higher: Will This Strength Last?
Avid Bioservices (CDMO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.